Continuing 100% MACE-free survival after two years average follow up in Heartcel clinical trial

Cell Therapy Ltd (“CTL”), a development stage pharmaceutical company with a portfolio of allogeneic regenerative medicines in clinical trials, reported average 24-month (19-29 months) MACE-free…